How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bupropion.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Wellbutrin — Competitive Intelligence Brief

Wellbutrin (bupropion) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NDRI (Norepinephrine-dopamine reuptake inhibitor). Area: Metabolic.

marketed NDRI (Norepinephrine-dopamine reuptake inhibitor) Cytochrome P450 2C19, Neuronal acetylcholine receptor subunit alpha-7, Alpha-1A adrenergic receptor Metabolic Small molecule Live · refreshed every 30 min

Target snapshot

Wellbutrin (bupropion) — GSK (GlaxoSmithKline). Norepinephrine-dopamine reuptake inhibitor (NDRI) that treats depression and aids smoking cessation without serotonergic side effects.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Wellbutrin TARGET	bupropion	GSK (GlaxoSmithKline)	marketed	NDRI (Norepinephrine-dopamine reuptake inhibitor)	Cytochrome P450 2C19, Neuronal acetylcholine receptor subunit alpha-7, Alpha-1A adrenergic receptor	1985-12-30
Wellbutrin	Wellbutrin	Mclean Hospital	marketed		Cytochrome P450 2C19, Neuronal acetylcholine receptor subunit alpha-7, Alpha-1A adrenergic receptor
Elontril	Elontril	Boehringer Ingelheim	phase 3		Cytochrome P450 2C19, Neuronal acetylcholine receptor subunit alpha-7, Alpha-1A adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (NDRI (Norepinephrine-dopamine reuptake inhibitor) class)

GSK (GlaxoSmithKline) · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Wellbutrin — Competitive Intelligence Brief. https://druglandscape.com/ci/bupropion. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab